I-Mab Gets Boost from Latest Industry Signals on New Cancer Treatment
Company’s shares surged as much as 15% after AstraZeneca unveiled upbeat results for a new class of cancer drugs known as CD73 antibodies Key Takeaways: I-Mab’s shares surged up to…
RELATED ARTICLES
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK - Cancer drug maker Genfleet joins Hong Kong IPO influx
-
AstraZeneca could face limited fallout from Chinese tax probe
AZN.US
-
Everest gets boost from core product Nefecon’s inclusion in China’s national health plan
1952.HK
-
NEWS WRAP: AstraZeneca China president assisting in investigation
AZN.US
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
